Clinical trials
Observational Breast Neoplasms trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
| Recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| University Hospital, Basel, Switzerland | 2 |
| AstraZeneca | 1 |
| European Breast Cancer Research Association of Surgical Trialists | 1 |
| Hoffmann-La Roche | 1 |
| Instituto de Investigacion Sanitaria La Fe | 1 |
| Jagiellonian University | 1 |
| Jules Bordet Institute | 1 |
| National Cancer Institute (NCI) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 19 |
| Lung Neoplasms | 3 |
| Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| Chemotherapy-Induced Febrile Neutropenia | 2 |
| Endometrial Neoplasms | 2 |
| Prostatic Neoplasms | 2 |
| Urinary Bladder Neoplasms | 2 |
| Anemia | 1 |
| Cardiotoxicity | 1 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.